Wedbush Reiterates Neutral Rating for Keros Therapeutics (NASDAQ:KROS)

Wedbush reaffirmed their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS - Free Report) in a research note released on Friday,Benzinga reports. The brokerage currently has a $15.00 price objective on the stock.

Several other equities analysts also recently commented on KROS. Scotiabank lowered their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. Truist Financial lowered their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Finally, HC Wainwright lowered their target price on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $37.00.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded up $0.25 during mid-day trading on Friday, reaching $14.27. The company had a trading volume of 480,221 shares, compared to its average volume of 847,768. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37. The stock has a market capitalization of $579.58 million, a PE ratio of -2.74 and a beta of 1.32. The stock's 50 day moving average is $13.00 and its 200-day moving average is $19.42.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. The firm had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period in the prior year, the business posted ($1.21) earnings per share. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current year.

Insider Buying and Selling at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was acquired at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This represents a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 20.60% of the company's stock.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently made changes to their positions in KROS. Barclays PLC lifted its stake in shares of Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after buying an additional 35,022 shares during the period. SG Americas Securities LLC bought a new stake in shares of Keros Therapeutics in the fourth quarter valued at about $388,000. Exchange Traded Concepts LLC bought a new stake in shares of Keros Therapeutics in the fourth quarter valued at about $99,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after buying an additional 1,372 shares during the period. Finally, Handelsbanken Fonder AB lifted its stake in shares of Keros Therapeutics by 11.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock valued at $171,000 after buying an additional 1,100 shares during the period. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.